Hypothalamic-pituitary-adrenal cortical axis

Hormones, Brain and Behavior Online

Volumn , Issue , 2009, Pages 2319-2341

  Rhodes, M E ^a   McKlveen, J M ^a   Ripepi, D R ^a   Gentile, N E ^a  

^a SAINT VINCENT COLLEGE   (United States)

Author keywords

Adrenocorticotropic hormone (ACTH); Arginine vasopressin (AVP); Corticosteroids; Corticotropin releasing hormone (CRH); Glucocorticoids; HPA axis

Indexed keywords

EID: 84884761759     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008088783-8.00073-5     Document Type: Chapter

References (176)

1. Abelson J.L., Khan S., Liberzon I., Young E.A. HPA axis activity in patients with panic disorder: Review and synthesis of four studies. Depression and Anxiety 2007, 24:66-76.
2. AdinoffB., Junghanns K., Kiefer F., Krishnan-Sarin S. Suppression of the HPA axis stress-response: Implications for relapse. Alcoholism, Clinical and Experimental Research 2005, 29:1351-1355.
3. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Frontiers in Neuroendocrinology 1994, 15:321-350.
4. Aguilera G., Kiss A., Liu Y., Kamitakahara A. Negative regulation of corticotropin releasing factor expression and limitation of stress response. Stress 2007, 10:153-161.
5. Aguilera G., Rabadan-Diehl C. Regulation of vasopressin V1b receptors in the anterior pituitary gland of the rat. Experimental Physiology 2000, 85:19S-26S.
6. Aguilera G., Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation. Regulatory Peptides 2000, 96:23-29.
7. Aguilera G., Subburaju S., Young S., Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Progress in Brain Research 2008, 170:29-39.
8. Ahima R.S., Saper C.B., Flier J.S., Elmquist J.K. Leptin regulation of neuroendocrine systems. Frontiers in Neuroendocrinology 2000, 21:263-307.
9. Alescio-Lautier B., Metzger D., Soumireu-Mourat B. Central behavioral effects of vasopressin: Point and perspectives. Reviews in the Neurosciences 1993, 4:239-266.
10. Alescio-Lautier B., Paban V., Soumireu-Mourat B. Neuromodulation of memory in the hippocampus by vasopressin. European Journal of Pharmacology 2000, 405:63-72.
11. Angeli A., Minetto M., Dovio A., Paccotti P. The overtraining syndrome in athletes: A stress-related disorder. Journal of Endocrinological Investigation 2004, 27:603-612.
12. Antoni F.A. Hypothalamic control of adrenocorticotropin secretion: Advances since the discovery of 41-residue corticotropin-releasing factor. Endocrine Reviews 1986, 7:351-378.
13. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Frontiers in Neuroendocrinology 1993, 14:76-122.
14. Arborelius L., Owens M.J., Plotsky P.M., NemeroffC.B. The role of corticotropin-releasing factor in depression and anxiety disorders. Journal of Endocrinology 1999, 160:1-12.
15. Armario A. The hypothalamic-pituitary-adrenal axis: What can it tell us about stressors?. CNS Neurological Disorders - Drug Targets 2006, 5:485-501.
16. Arzt E., Pereda M.P., Castro C.P., Pagotto U., Renner U., Stalla G.K. Pathophysiological role of the cytokine network in the anterior pituitary gland. Frontiers in Neuroendocrinology 1999, 20:71-95.
17. Auernhammer C.J., Chesnokova V., Melmed S. Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 1998, 139:2201-2208.
18. Bao A.M., Meynen G., Swaab D.F. The stress system in depression and neurodegeneration: Focus on the human hypothalamus. Brain Research Reviews 2008, 57:531-553.
19. Bergh C., Sodersten P. Anorexia nervosa, self-starvation and the reward of stress. Nature Medicine 1996, 2:21-22.
20. Besedovsky H.O., del Rey A. The cytokine-HPA axis feed-back circuit. Zeitschrift fur Rheumatologie 2000, 59(supplement 2):II/26-II/30.
21. Bjorntorp P. Visceral obesity: A "civilization syndrome.". Obesity Research 1993, 1:206-222.
22. Bohus B., de Wied D. The vasopressin deficient Brattleboro rats: A natural knockout model used in the search for CNS effects of vasopressin. Progress in Brain Research 1998, 119:555-573.
23. Bremner J.D., Krystal J.H., Southwick S.M., Charney D.S. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 1996, 23:39-51.
24. Bruijnzeel A.W., Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Research. Brain Research Reviews 2005, 49:505-528.
25. Buckingham J.C. Glucocorticoids: Exemplars of multi-tasking. British Journal of Pharmacology 2006, 147(supplement 1):S258-S268.
26. Bugajski J. Role of prostaglandins in the stimulation of the hypothalamic-pituitary-adrenal axis by adrenergic and neurohormone systems. Journal of Physiology and Pharmacology 1996, 47:559-575.
27. Bundzikova J., Pirnik Z., Zelena D., Mikkelsen J.D., Kiss A. Response of substances co-expressed in hypothalamic magnocellular neurons to osmotic challenges in normal and Brattleboro rats. Cellular and Molecular Neurobiology 2008, 28:1033-1047.
28. Caldwell H.K., Lee H.J., Macbeth A.H., Young W.S. Vasopressin: Behavioral roles of an "original" neuropeptide. Progress in Neurobiology 2008, 84:1-24.
29. Calogero A.E., Bernardini R., Gold P.W., Chrousos G.P. Regulation of rat hypothalamic corticotropin-releasing hormone secretion in vitro: Potential clinical implications. Advances in Experimental Medicine and Biology 1988, 245:167-181.
30. Caso J.R., Leza J.C., Menchen L. The effects of physical and psychological stress on the gastro-intestinal tract: Lessons from animal models. Current Molecular Medicine 2008, 8:299-312.
31. Castro M., Moreira A.C. Regulation of corticotropin-releasing hormone secretion by ACTH at different times after adrenalectomy. Brazilian Journal of Medical and Biological Research 1996, 29:1573-1578.
32. Chalmers D.T., Lovenberg T.W., De Souza E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression. Journal of Neuroscience 1995, 15:6340-6350.
33. Charmandari E., Tsigos C., Chrousos G. Endocrinology of the stress response. Annual Review of Physiology 2005, 67:259-284.
34. Chrousos G.P. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye memorial lecture. Annals of the New York Academy of Sciences 1998, 851:311-335.
35. Chrousos G.P. The HPA axis and the stress response. Endocrine Research 2000, 26:513-514.
36. Chrousos G.P. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: Neuro-endocrine and target tissue-related causes. International Journal of Obesity and Related Metabolic Disorders 2000, 24(supplement 2):S50-S55.
37. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. Journal of the American Medical Association 1992, 267:1244-1252.
38. Claes S.J. Corticotropin-releasing hormone (CRH) in psychiatry: From stress to psychopathology. Annals of Medicine 2004, 36:50-61.
39. Claes S.J. CRH, stress, and major depression: A psychobiological interplay. Vitamins and Hormones 2004, 69:117-150.
40. Clarke T.K., Treutlein J., Zimmermann U.S., et al. HPA-axis activity in alcoholism: Examples for a gene-environment interaction. Addiction Biology 2008, 13:1-14.
41. Cone R.D., Mountjoy K.G. Molecular genetics of the ACTH and melanocyte-stimulating hormone receptors. Trends in Endocrinology and Metabolism 1993, 4:242-247.
42. Crofton J.T., Share L., Brooks D.P. Pressor responsiveness to and secretion of vasopressin during the estrous cycle. American Journal of Physiology 1988, 255:R1041-R1048.
43. Crowell M.D., Jones M.P., Harris L.A., Dineen T.N., Schettler V.A., Olden K.W. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes. Current Opinion in Investigational Drugs 2004, 5:736-742.
44. Dallman M.F., Akana S.F., Laugero K.D., Gomez F., Manalo S., Bell M.E., Bhatnagar S. A spoonful of sugar: Feedback signals of energy stores and corticosterone regulate responses to chronic stress. Physiology and Behavior 2003, 79:3-12.
45. Dinan T.G., O'Brien S., Lavelle E., Scott L.V. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychological Medicine 2004, 34:169-172.
46. Dinan T.G., Scott L.V. Anatomy of melancholia: Focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. Journal of Anatomy 2005, 207:259-264.
47. Donaldson Z.R., Young L.J. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 2008, 322:900-904.
48. Dubois-Dauphin M., Barberis C., De Bilbao F. Vasopressin receptors in the mouse (Mus musculus) brain: Sex-related expression in the medical preoptic area and hypothalamus. Brain Research 1996, 743:32-39.
49. Dubois-Dauphin M., Pevet P., Tribollet E., Dreifuss J. Vasopressin in the brain of the golden hamster: The distribution of vasopressin binding sites and of immunoreactivity to the vasopressin-related glycopeptide. Journal of Comparative Neurology 1990, 300:535-548.
50. Dunn A.J. Cytokine activation of the HPA axis. Annals of the New York Academy of Sciences 2000, 917:608-617.
51. Engelmann M., Landgraf R., Wotjak C.T. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: An old concept revisited. Frontiers in Neuroendocrinology 2004, 25:132-149.
52. Fehm H.L., Kern W., Peters A. The selfish brain: Competition for energy resources. Progress in Brain Research 2006, 153:129-140.
53. Filaretova L., Bagaeva T., Podvigina T., Makara G. Various ulcerogenic stimuli are potentiated by glucocorticoid deficiency in rats. Journal of Physiology (Paris) 2001, 95:59-65.
54. Filaretova L., Podvigina T., Bagaeva T., Bobryshev P., Takeuchi K. Gastroprotective role of glucocorticoid hormones. Journal of Pharmacological Sciences 2007, 104:195-201.
55. Gabry K.E., Gold P.W., Chrousos G.P. Hypothalamic-pituitary-adrenal axis: Introduction to physiology and pathophysiology. Hormones, Brain, and Behavior 2002, vol. 4:841-866. Academic Press, New York. D. Pfaff(Ed.).
56. Geracioti T.D., Orth D.N., Ekhator N.N., Blumenkopf B., Loosen P.T. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. Journal of Clinical Endocrinology and Metabolism 1992, 74:1325-1330.
57. Gilligan P.J., Robertson D.W., Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents. Journal of Medicinal Chemistry 2000, 43:1641-1660.
58. Goeders N.E. The impact of stress on addiction. European Neuropsychopharmacology 2003, 13:435-441.
59. Gold P.W., Chrousos G.P. The endocrinology of melancholic and atypical depression: Relation to neurocircuitry and somatic consequences. Proceedings of the Association of American Physicians 1999, 111:22-34.
60. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Molecular Psychiatry 2002, 7:254-275.
61. Gold P.W., Pigott T.A., Kling M.A., Kalogeras K., Chrousos G.P. Basic and clinical studies with corticotropin-releasing hormone. Implications for a possible role in panic disorder. Psychiatric Clinics of North America 1988, 11:327-334.
62. Gold P.W., Wong M.L., Chrousos G.P., Licinio J. Stress system abnormalities in melancholic and atypical depression: Molecular, pathophysiological, and therapeutic implications. Molecular Psychiatry 1996, 1:257-264.
63. Grant F.D. Genetic models of vasopressin deficiency. Experimental Physiology 2000, 85:203S-209S.
64. Grigoriadis D.E., Heroux J.A., De Souza E.B. Characterization and regulation of corticotropin-releasing factor receptors in the central nervous, endocrine and immune systems. Ciba Foundation Symposium 1993, 172:85-101. discussion 101-107.
65. Habib K.E., Gold P.W., Chrousos G.P. Neuroendocrinology of stress. Endocrinology and Metabolism Clinics of North America 2001, 30:695-728. vii-viii.
66. Heesen C., Gold S.M., Huitinga I., Reul J.M. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review. Psychoneuroendocrinology 2007, 32:604-618.
67. Heinrichs M., Domes G. Neuropeptides and social behaviour: Effects of oxytocin and vasopressin in humans. Progress in Brain Research 2008, 170:337-350.
68. Herman J.P., Seroogy K. Hypothalamic-pituitary-adrenal axis, glucocorticoids, and neurologic disease. Neurologic Clinics 2006, 24:461-481. vi.
69. Higuchi H., Hasegawa A., Yamaguchi T. Transcriptional regulation of neuronal genes and its effect on neural functions: Transcriptional regulation of neuropeptide Y gene by leptin and its effect on feeding. Journal of Pharmacological Sciences 2005, 98:225-231.
70. Hiroshige T., Wada-Okada S. Diurnal changes of hypothalamic content of corticotropin-releasing activity in female rats at various stages of the estrous cycle. Neuroendocrinology 1973, 12:316-319.
71. Hofman M.A. Lifespan changes in the human hypothalamus. Experimental Gerontology 1997, 32:559-575.
72. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine 2001, 7:605-611.
73. Jacobson L. Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinology and Metabolism Clinics of North America 2005, 34:271-292. vii.
74. Jimerson D.C. Leptin and the neurobiology of eating disorders. Journal of Laboratory and Clinical Medicine 2002, 139:70-71.
75. Jimerson D.C., Wolfe B.E. Neuropeptides in eating disorders. CNS Spectrums 2004, 9:516-522.
76. Johnson E.O., Kamilaris T.C., Chrousos G.P., Gold P.W. Mechanisms of stress: A dynamic overview of hormonal and behavioral homeostasis. Neuroscience and Biobehavioral Reviews 1992, 16:115-130.
77. Jones M.P., Dilley J.B., Drossman D., Crowell M.D. Brain-gut connections in functional GI disorders: Anatomic and physiologic relationships. Neurogastroenterology and Motility 2006, 18:91-103.
78. Junghanns K., Backhaus J., Tietz U., et al. Impaired serum cortisol stress response is a predictor of early relapse. Alcohol and Alcoholism 2003, 38:189-193.
79. Kasting N.W. Simultaneous and independent release of vasopressin and oxytocin in the rat. Canadian Journal of Physiology and Pharmacology 1988, 66:22-26.
80. Kasting N.W. Criteria for establishing a physiological role for brain peptides a case in point: The role of vasopressin in thermoregulation during fever and antipyresis. Brain Research Reviews 1989, 14:143-153.
81. Kaye W.H., Berrettini W., Gwirtsman H., George D.T. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Archives of General Psychiatry 1990, 47:548-556.
82. Keck M.E. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids 2006, 31:241-250.
83. Kelesidis T., Mantzoros C.S. The emerging role of leptin in humans. Pediatric Endocrinology Reviews 2006, 3:239-248.
84. Keller-Wood M., Dallman M. Corticosteroid inhibition of ACTH secretion. Endocrine Reviews 1984, 5:1-24.
85. Khatri P., Blumenthal J.A. Exercise. Encyclopedia of Stress 2007, vol. 1:982-986. Elsevier, Oxford. G. Fink (Ed.).
86. Kiefer F., Jahn H., Otte C., Naber D., Wiedemann K. Hypothalamic-pituitary-adrenocortical axis activity: A target of pharmacological anticraving treatment?. Biological Psychiatry 2006, 60:74-76.
87. Kiefer F., Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addiction Biology 2004, 9:205-212.
88. Kovacs K.J., Foldes A., Sawchenko P.E. Glucocorticoid negative feedback selectively targets vasopressin transcription in parvocellular neurosecretory neurons. Journal of Neuroscience 2000, 20:3843-3852.
89. Kovacs K.J., Sawchenko P.E. Sequence of stress-induced alterations in indices of synaptic and transcriptional activation in parvocellular neurosecretory neurons. Journal of Neuroscience 1996, 16:262-273.
90. Kudielka B.M., Kirschbaum C. Sex differences in HPA axis responses to stress: A review. Biological Psychology 2005, 69:113-132.
91. Lamberts S.W., Huizenga A.T., de Lange P., de Jong F.H., Koper J.W. Clinical aspects of glucocorticoid sensitivity. Steroids 1996, 61:157-160.
92. Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurological Disorders - Drug Targets 2006, 5:167-179.
93. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: A dynamic concept of multiple and variable modes of neuropeptide communication. Frontiers in Neuroendocrinology 2004, 25:150-176.
94. Laue L., Gold P.W., Richmond A., Chrousos G.P. The hypothalamic-pituitary-adrenal axis in anorexia nervosa and bulimia nervosa: Pathophysiologic implications. Advances in Pediatrics 1991, 38:287-316.
95. Leonard B.E. HPA and immune axes in stress: Involvement of the serotonergic system. Neuroimmunomodulation 2006, 13:268-276.
96. Lewis K., Li C., Perrin M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:7570-7575.
97. Licinio J., Wong M.L., Gold P.W. The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Research 1996, 62:75-83.
98. Lupien S.J., Fiocco A., Wan N., Maheu F., Lord C., Schramek T., Tu M.T. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology 2005, 30:225-242.
99. Lupien S.J., Gillin C.J., Hauger R.L. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: A dose-response study in humans. Behavioral Neuroscience 1999, 113:420-430.
100. Madeira M.D., Lieberman A.R. Sexual dimorphism in the mammalian limbic system. Progress in Neurobiology 1995, 45:275-333.
101. Magri F., Cravello L., Barili L., et al. Stress and dementia: The role of the hypothalamic-pituitary-adrenal axis. Aging Clinical and Experimental Research 2006, 18:167-170.
102. Makrigiannakis A., Psychoyos A., Zoumakis E., Margioris A.N., Stournaras C., Gravanis A. Endometrial corticotropin-releasing hormone: Expression, regulation, and potential physiological implications. Annals of the New York Academy of Sciences 1997, 816:116-128.
103. Mantzoros C.S. The role of leptin in human obesity and disease: A review of current evidence. Annals of Internal Medicine 1999, 130:671-680.
104. Mantzoros C.S., Moschos S.J. Leptin: In search of role(s) in human physiology and pathophysiology. Clinical Endocrinology (Oxf) 1998, 49:551-567.
105. Margioris A.N., Grino M., Rabin D., Chrousos G.P. Human placenta and the hypothalamic-pituitary-adrenal axis. Advances in Experimental Medicine and Biology 1988, 245:389-398.
106. Marquez C., Nadal R., Armario A. Responsiveness of the hypothalamic-pituitary-adrenal axis to different novel environments is a consistent individual trait in adult male outbred rats. Psychoneuroendocrinology 2005, 30:179-187.
107. Mastorakos G., Pavlatou M. Exercise as a stress model and the interplay between the hypothalamus-pituitary-adrenal and the hypothalamus-pituitary-thyroid axes. Hormones and Metabolic Research 2005, 37:577-584.
108. Mastorakos G., Pavlatou M., Diamanti-Kandarakis E., Chrousos G.P. Exercise and the stress system. Hormones (Athens) 2005, 4:73-89.
109. McEwen B.S. Allostasis, allostatic load, and the aging nervous system: Role of excitatory amino acids and excitotoxicity. Neurochemical Research 2000, 25:1219-1231.
110. McEwen B.S. Sex, stress and the hippocampus: Allostasis, allostatic load and the aging process. Neurobiology of Aging 2002, 23:921-939.
111. McEwen B.S. Physiology and neurobiology of stress and adaptation: Central role of the brain. Physiological Reviews 2007, 87:873-904.
112. Meynen G., Unmehopa U.A., van Heerikhuize J.J., Hofman M.A., Swaab D.F., Hoogendijk W.J. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biological Psychiatry 2006, 60:892-895.
113. Mlynarik M., Zelena D., Bagdy G., Makara G.B., Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Hormones and Behavior 2007, 51:395-405.
114. Monnikes H., Tebbe J.J., Hildebrandt M., et al. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Digestive Diseases 2001, 19:201-211.
115. Mountjoy K.G., Robbins L.S., Mortrud M.T., Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science 1992, 257:1248-1251.
116. Munck A. Glucocorticoid receptors and physiology: A personal history. Steroids 2005, 70:335-344.
117. Munck A., Guyre P.M., Holbrook N.J. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrine Reviews 1984, 5:25-44.
118. Owens M.J., NemeroffC.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Reviews 1991, 43:425-473.
119. Palkovits M., Brownstein M.J., Vale W. Distribution of corticotropin-releasing factor in rat brain. Federation Proceedings 1985, 44:215-219.
120. Plotsky P., Otto S., Toyama T., Sutton S. Lack of correlation between immunoreactive corticotropin-releasing factor concentration profiles in hypophysial-portal and peripheral plasma. Journal of Neuroendocrinology 1990, 2:65-69.
121. Plotsky P.M. Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology 1987, 121:924-930.
122. Plotsky P.M., Cunningham E.T., Widmaier E.P. Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocrine Reviews 1989, 10:437-458.
123. Pomara N., Greenberg W.M., Branford M.D., Doraiswamy P.M. Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: Review and update. Psychopharmacology Bulletin 2003, 37:120-134.
124. Pothoulakis C., Castagliuolo I., Leeman S.E. Neuroimmune mechanisms of intestinal responses to stress. Role of corticotropin-releasing factor and neurotensin. Annals of the New York Academy of Sciences 1998, 840:635-648.
125. Rassnick S., Sved A.F., Rabin B.S. Locus coeruleus stimulation by corticotropin-releasing hormone suppresses in vitro cellular immune responses. Journal of Neuroscience 1994, 14:6033-6040.
126. Reyes T.M., Lewis K., Perrin M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:2843-2848.
127. Rhodes M.E. Adrenocorticotropic hormone (ACTH). Encyclopedia of Stress 2007, vol. 1:69-72. Academic Press, Oxford. G. Fink (Ed.).
128. Rhodes M.E., Balestreire E.M., Czambel R.K., Rubin R.T. Estrous cycle influences on sexual diergism of HPA axis responses to cholinergic stimulation in rats. Brain Research Bulletin 2002, 59:217-225.
129. Rhodes M.E., Kennell J.S., Belz E.E., Czambel R.K., Rubin R.T. Rat estrous cycle influences the sexual diergism of HPA axis stimulation by nicotine. Brain Research Bulletin 2004, 64:205-213.
130. Rhodes M.E., O'Toole S.M., Czambel R.K., Rubin R.T. Male-female differences in rat hypothalamic-pituitary-adrenal axis responses to nicotine stimulation. Brain Research Bulletin 2001, 54:681-688.
131. Rhodes M.E., O'Toole S.M., Wright S.L., Czambel R.K., Rubin R.T. Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism. Brain Research Bulletin 2001, 54:101-113.
132. Rhodes M.E., Rubin R.T. Functional sex differences ('sexual diergism') of central nervous system cholinergic systems, vasopressin, and hypothalamic-pituitary-adrenal axis activity in mammals: A selective review. Brain Research. Brain Research Reviews 1999, 30:135-152.
133. Rivier C., Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 1983, 305:325-327.
134. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obesity Research 2002, 10:1078-1086.
135. Rubin R.T., O'Toole S.M., Rhodes M.E., Sekula L.K., Czambel R.K. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: Sex differences between major depressives and matched control subjects. Psychiatry Research 1999, 89:1-20.
136. Rubin R.T., Rhodes M.E., Czambel R.K. Sexual diergism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls. Psychiatry Research 2002, 113:255-268.
137. Sahu A. Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology 1998, 139:795-798.
138. Sahu A. Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat. Endocrinology 1998, 139:4739-4742.
139. Sahu A. Leptin signaling in the hypothalamus: Emphasis on energy homeostasis and leptin resistance. Frontiers in Neuroendocrinology 2003, 24:225-253.
140. Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004, 145:2613-2620.
141. Sahu A. Effects of chronic central leptin infusion on proopiomelanocortin and neurotensin gene expression in the rat hypothalamus. Neuroscience Letters 2008, 440:125-129.
142. Saphier D., Welch J.E., Farrar G.E., Nguyen N.Q., Aguado F., Thaller T.R., Knight D.S. Interactions between serotonin, thyrotropin-releasing hormone, and substance P in the CNS regulation of adrenocortical secretion. Psychoneuroendocrinology 1994, 19:779-797.
143. Sapolsky R.M., Romero L.M., Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocrine Reviews 2000, 21:55-89.
144. Sawchenko P.E., Benoit R., Brown M.R. Somatostatin 28-immunoreactive inputs to the paraventricular and supraoptic nuclei: Principal origin from non-aminergic neurons in the nucleus of the solitary tract. Journal of Chemical Neuroanatomy 1988, 1:81-94.
145. Sawchenko P.E., Plotsky P.M., Pfeiffer S.W., Cunningham E.T., Vaughan J., Rivier J., Vale W. Inhibin beta in central neural pathways involved in the control of oxytocin secretion. Nature 1988, 334:615-617.
146. Scott L.V., Dinan T.G. Vasopressin as a target for antidepressant development: An assessment of the available evidence. Journal of Affective Disorders 2002, 72:113-124.
147. Selye H. A syndrome produced by diverse nocuous agents. Nature 1936, 138:32.
148. Selye H. Forty years of stress research: Principal remaining problems and misconceptions. Canadian Medical Association Journal 1976, 115:53-56.
149. Simerly R.B., Chang C., Muramatsu M., Swanson L.W. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization study. Journal of Comparative Neurology 1990, 294:76-95.
150. Smith M.A., Kling M.A., Whitfield H.J., et al. Corticotropin-releasing hormone: From endocrinology to psychobiology. Hormone Research 1989, 31:66-71.
151. Smith S.M., Vale W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in Clinical Neuroscience 2006, 8:383-395.
152. Southwick S.M., Bremner J.D., Rasmusson A., Morgan C.A., Arnsten A., Charney D.S. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biological Psychiatry 1999, 46:1192-1204.
153. Southwick S.M., Paige S., Morgan C.A., Bremner J.D., Krystal J.H., Charney D.S. Neurotransmitter alterations in PTSD: Catecholamines and serotonin. Seminars in Clinical Neuropsychiatry 1999, 4:242-248.
154. Southwick S.M., Vythilingam M., Charney D.S. The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annual Review of Clinical Psychology 2005, 1:255-291.
155. Spinedi E., Johnston C.A., Chisari A., Negro-Vilar A. Role of central epinephrine on the regulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocrinology 1988, 122:1977-1983.
156. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biological Psychiatry 1999, 46:1480-1508.
157. Suescun M.O., Chisari A., Gaillard R.C., Spinedi E. Age and sex steroid environment modulate hypothalamo-pituitary-adrenal axis function in mice. Endocrinology and Metabolism 1997, 4:179-184.
158. Surget A., Belzung C. Involvement of vasopressin in affective disorders. European Journal of Pharmacology 2008, 583:340-349.
159. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 1983, 36:165-186.
160. Thrivikraman K.V., NemeroffC.B., Plotsky P.M. Sensitivity to glucocorticoid-mediated fast-feedback regulation of the hypothalamic-pituitary-adrenal axis is dependent upon stressor specific neurocircuitry. Brain Research 2000, 870:87-101.
161. Tichomirowa M.A., Keck M.E., Schneider H.J., Paez-Pereda M., Renner U., Holsboer F., Stalla G.K. Endocrine disturbances in depression. Journal of Endocrinological Investigation 2005, 28:89-99.
162. Tsigos C., Chrousos G.P. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinology and Metabolism Clinics of North America 1994, 23:451-466.
163. Turnbull A.V., Rivier C. Regulation of the HPA axis by cytokines. Brain Behavior and Immunity 1995, 9:253-275.
164. Vale W., Spiess J., River C., River J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213:1394-1397.
165. van Londen L., Goekoop J.G., van Kempen G.M., et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17:284-292.
166. Vaughan J., Donaldson C., Bittencourt J., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378:287-292.
167. Versteeg C.A., Cransberg K., De Jong W., Bohus B. Reduction of a centrally induced pressor response by neurohypophyseal peptides: The involvement of lower brainstem mechanisms. European Journal of Pharmacology 1983, 94:133-140.
168. Vicennati V., Ceroni L., Genghini S., Patton L., Pagotto U., Pasquali R. Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obesity (Silver Spring) 2006, 14:235-243.
169. Vicennati V., Pasquali R. Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: Evidence for a central and a peripheral alteration. Journal of Clinical Endocrinology and Metabolism 2000, 85:4093-4098.
170. Vinson G.P., Whitehouse B.J., Hinson J.P. Adrenal cortex. Encyclopedia of Stress 2007, vol. 1:38-46. Elsevier, Oxford. G. Fink (Ed.).
171. Wallon C., Yang P.C., Keita A.V., et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008, 57:50-58.
172. Wessinger S., Jones M.P., Crowell M.D. Editorial overview: Serotonergic agents in functional GI disorders: Targeting the brain-gut axis. Current Opinion in Investigational Drugs 2005, 6:663-666.
173. Westphal N.J., Evans R.T., Seasholtz A.F. Novel expression of type 1 CRH receptor in multiple endocrine cell types in the murine anterior pituitary. Endocrinology 2009, 150:260-267.
174. Whitnall M. Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system. Progress in Neurobiology 1993, 40:573-629.
175. Wolf O.T. HPA axis and memory. Best Practice and Research. Clinical Endocrinology and Metabolism 2003, 17:287-299.
176. Wolf O.T., Convit A., McHugh P.F., et al. Cortisol differentially affects memory in young and elderly men. Behavioral Neuroscience 2001, 115:1002-1011.